Literature DB >> 21406497

Prevalence of and factors associated with hypertension in young and old women with systemic lupus erythematosus.

José Mario Sabio1, José Antonio Vargas-Hitos, Nuria Navarrete-Navarrete, Juan Diego Mediavilla, Juan Jiménez-Jáimez, Antonio Díaz-Chamorro, Juan Jiménez-Alonso.   

Abstract

OBJECTIVE: Hypertension (HT) is more prevalent in patients with systemic lupus erythematosus (SLE) than among the general population and it has been associated with atherosclerotic cardiovascular diseases in these patients. We examined the proportion of HT and factors associated with it in young and old women with SLE.
METHODS: Participants (112 women with SLE and 223 healthy age-matched women) were categorized as young (age ≤ 40 years) or old (age > 40 years). We compared cardiovascular and specific SLE-related variables and inflammatory markers in hypertensive and normotensive women with SLE for each age range. We also assessed the factors independently associated with HT in the entire cohort and in each age range by means of a multivariate regression analysis.
RESULTS: The prevalence of HT was higher in women with SLE than in controls (56% vs 29%; p < 0.001), and was proportionally higher in younger women with SLE (40% vs 11%; p < 0.001) than in older women with SLE (74% vs 47%; p = 0.001). After adjustment for potential confounders, HT was associated with renal involvement and higher nonobesity-related insulin levels in younger women with SLE. In older patients, HT was associated with age, renal involvement, and obesity. Finally, in the entire cohort, HT was associated with age, insulin, renal involvement, and the Systemic Lupus Erythematosus Disease Activity Index score.
CONCLUSION: An association between HT and insulin has been identified in women with SLE, particularly younger ones. Factors associated with HT in women with SLE differed depending on their age. HT was more prevalent in women with SLE than in control subjects, being proportionally higher in young women with SLE.

Entities:  

Mesh:

Year:  2011        PMID: 21406497     DOI: 10.3899/jrheum.101132

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  46 in total

1.  Anti-CD3 antibody therapy attenuates the progression of hypertension in female mice with systemic lupus erythematosus.

Authors:  Keisa W Mathis; Erin B Taylor; Michael J Ryan
Journal:  Pharmacol Res       Date:  2017-04-08       Impact factor: 7.658

2.  Association of estimated sodium and potassium intake with blood pressure in patients with systemic lupus erythematosus.

Authors:  A Barnado; A Oeser; Y Zhang; C R Okafor; J Titze; C M Stein; C P Chung
Journal:  Lupus       Date:  2016-07-11       Impact factor: 2.911

3.  Preventing autoimmunity protects against the development of hypertension and renal injury.

Authors:  Keisa W Mathis; Kedra Wallace; Elizabeth R Flynn; Christine Maric-Bilkan; Babbette LaMarca; Michael J Ryan
Journal:  Hypertension       Date:  2014-07-14       Impact factor: 10.190

4.  Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE.

Authors:  Victoria L Wolf; Taylor L Phillips; Erin B Taylor; Jennifer M Sasser; Michael J Ryan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

Review 5.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

6.  A population-based study of risk factors for heart failure in pediatric and adult-onset systemic lupus erythematosus.

Authors:  Joyce C Chang; Rui Xiao; Andrea M Knight; Stephen E Kimmel; Laura M Mercer-Rosa; Pamela F Weiss
Journal:  Semin Arthritis Rheum       Date:  2020-05-03       Impact factor: 5.532

7.  Tissue sodium content in patients with systemic lupus erythematosus: association with disease activity and markers of inflammation.

Authors:  D A Carranza-León; A Oeser; A Marton; P Wang; J C Gore; J Titze; C M Stein; C P Chung; M J Ormseth
Journal:  Lupus       Date:  2020-02-18       Impact factor: 2.911

Review 8.  Role of the Immune System in Hypertension.

Authors:  Bernardo Rodriguez-Iturbe; Hector Pons; Richard J Johnson
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

9.  Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease.

Authors:  Erin B Taylor; Michelle T Barati; David W Powell; Hannah R Turbeville; Michael J Ryan
Journal:  Hypertension       Date:  2018-01-29       Impact factor: 10.190

10.  17β-Estradiol protects against the progression of hypertension during adulthood in a mouse model of systemic lupus erythematosus.

Authors:  Emily L Gilbert; Keisa W Mathis; Michael J Ryan
Journal:  Hypertension       Date:  2013-12-23       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.